Thursday - December 25, 2025
Finerenone Approved in Japan for Treatment of Patients With Chronic Heart Failure
December 22, 2025
LEVERKUSEN, Germany, Dec. 22 -- Bayer, a pharmaceutical and life sciences company, issued the following news release:

* * *

Finerenone approved in Japan for treatment of patients with chronic heart failure

MHLW approves finerenone in Japan for chronic heart failure, introducing a new therapeutic option for patients with chronic heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e. mildly reduced or preserved LVEF / Finerenone (Ker . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products